Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)’s traded shares stood at 0.51 million during the latest session, with the company’s beta value hitting 0.64. At the last check today, the stock’s price was $4.16, to imply an increase of 4.65% or $0.18 in intraday trading. The GLMD share’s 52-week high remains $10.50, putting it -152.4% down since that peak but still an impressive 34.38% since price per share fell to its 52-week low of $2.73. The company has a valuation of $2.67M, with an average of 0.14 million shares in intraday trading volume over the past 10 days and average of 53.38K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Galmed Pharmaceuticals Ltd (GLMD), translating to a mean rating of 1.00. Of 7 analyst(s) looking at the stock, 0 analyst(s) give GLMD a Sell rating. 0 of those analysts rate the stock as Overweight while 3 advise Hold as 4 recommend it as a Buy.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) trade information
After registering a 4.65% upside in the latest session, Galmed Pharmaceuticals Ltd (GLMD) has traded red over the past five days. The 5-day price performance for the stock is 37.91%, and 20.30% over 30 days. With these gigs, the year-to-date price performance is -23.72%. Short interest in Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) saw shorts transact 40640.0 shares and set a 0.42 days time to cover.
GLMD Dividends
Galmed Pharmaceuticals Ltd has its next earnings report out on 2024-Apr-04. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)’s Major holders
We also have Delaware Group Equity Fds IV-Delaware Healthcare Fund and Fidelity NASDAQ Composite Index Fund as the top two Mutual Funds with the largest holdings of the Galmed Pharmaceuticals Ltd (GLMD) shares. Going by data provided on Jun 30, 2024, Delaware Group Equity Fds IV-Delaware Healthcare Fund holds roughly 1.7 shares. This is just over 0.26% of the total shares, with a market valuation of $6630.0. Data from the same date shows that the other fund manager holds a little less at 151.0, or 0.02% of the shares, all valued at about 588.0.
